These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 24916545)
1. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cheng L; Ren W; Xie L; Li M; Liu J; Hu J; Liu BR; Qian XP Cancer Chemother Pharmacol; 2014 Jul; 74(1):1-13. PubMed ID: 24916545 [TBL] [Abstract][Full Text] [Related]
2. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
4. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Patel DK Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550 [TBL] [Abstract][Full Text] [Related]
5. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
6. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Fakih M Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
8. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366 [TBL] [Abstract][Full Text] [Related]
11. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. Song QB; Wang Q; Hu WG World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888 [TBL] [Abstract][Full Text] [Related]
12. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Ouwerkerk J; Boers-Doets C Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896 [TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544 [TBL] [Abstract][Full Text] [Related]
14. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. You B; Chen EX J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284 [TBL] [Abstract][Full Text] [Related]
18. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. Burtness B Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776 [TBL] [Abstract][Full Text] [Related]
20. [Predictive factors of response to anti-EGFR treatments in colorectal cancer]. Lièvre A; Laurent-Puig P Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]